The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Arkin     6-[4-(3,4-dimethoxyphenyl) carbonylpiperazi...

Synonyms: Vesnarinona, vesnarinone, Vesnarinonum, Arkin-Z, CHEMBL17423, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of vesnarinone


Psychiatry related information on vesnarinone


High impact information on vesnarinone


Chemical compound and disease context of vesnarinone


Biological context of vesnarinone


Anatomical context of vesnarinone


Associations of vesnarinone with other chemical compounds


Gene context of vesnarinone


Analytical, diagnostic and therapeutic context of vesnarinone


  1. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. Feldman, A.M., Bristow, M.R., Parmley, W.W., Carson, P.E., Pepine, C.J., Gilbert, E.M., Strobeck, J.E., Hendrix, G.H., Powers, E.R., Bain, R.P. N. Engl. J. Med. (1993) [Pubmed]
  2. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. Cohn, J.N., Goldstein, S.O., Greenberg, B.H., Lorell, B.H., Bourge, R.C., Jaski, B.E., Gottlieb, S.O., McGrew, F., DeMets, D.L., White, B.G. N. Engl. J. Med. (1998) [Pubmed]
  3. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production. Matsui, S., Matsumori, A., Matoba, Y., Uchida, A., Sasayama, S. J. Clin. Invest. (1994) [Pubmed]
  4. Immunomodulation: a new horizon for medical treatment of heart failure. Sasayama, S., Matsumori, A., Matoba, Y., Matsui, S., Yamada, T., Shioi, T., Sato, Y., Doyama, K., Kishimoto, C. J. Card. Fail. (1996) [Pubmed]
  5. OPC-8212 in the treatment of congestive heart failure: results of a pilot study. Kubo, S.H., Rector, T.S., Strobeck, J.E., Cohn, J.N. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1988) [Pubmed]
  6. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. Kubota, T., McNamara, D.M., Wang, J.J., Trost, M., McTiernan, C.F., Mann, D.L., Feldman, A.M. Circulation (1998) [Pubmed]
  7. Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K+ current. Toyama, J., Kamiya, K., Cheng, J., Lee, J.K., Suzuki, R., Kodama, I. Circulation (1997) [Pubmed]
  8. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. Reis, S.E., Holubkov, R., Young, J.B., White, B.G., Cohn, J.N., Feldman, A.M. J. Am. Coll. Cardiol. (2000) [Pubmed]
  9. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. Gardner, I., Popović, M., Zahid, N., Uetrecht, J.P. Chem. Res. Toxicol. (2005) [Pubmed]
  10. The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis. Jiang, H., Bielekova, B., Okazaki, H., Clarence-Smith, K., Johnson, K.P., Bergey, G., Martin, R., Dhib-Jalbut, S. J. Neuroimmunol. (1999) [Pubmed]
  11. Effects of a new forskolin derivative, NKH477, on canine ventricular arrhythmia models. Hirasawa, A., Awaji, T., Hosono, M., Haruno, A., Hashimoto, K. J. Cardiovasc. Pharmacol. (1993) [Pubmed]
  12. Effects of OPC-8212, a new positive inotropic agent, and dobutamine on left ventricular global and ischemic regional functions and coronary hemodynamics under coronary artery stenosis. Maruyama, Y., Nishioka, O., Watanabe, J., Keitoku, M., Satoh, S., Isoyama, S., Ashikawa, K., Ino-Oka, E., Takishima, T. J. Cardiovasc. Pharmacol. (1986) [Pubmed]
  13. Inhibition of CD4 cross-linking-induced lymphocytes apoptosis by vesnarinone as a novel immunomodulating agent: vesnarinone inhibits Fas expression and apoptosis by blocking cytokine secretion. Oyaizu, N., McCloskey, T.W., Than, S., Pahwa, S. Blood (1996) [Pubmed]
  14. Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer. Patnaik, A., Rowinsky, E.K., Tammara, B.K., Hidalgo, M., Drengler, R.L., Garner, A.M., Siu, L.L., Hammond, L.A., Felton, S.A., Mallikaarjun, S., Von Hoff, D.D., Eckhardt, S.G. J. Clin. Oncol. (2000) [Pubmed]
  15. Vesnarinone suppresses TNF-induced activation of NF-kappa B, c-Jun kinase, and apoptosis. Manna, S.K., Aggarwal, B.B. J. Immunol. (2000) [Pubmed]
  16. Alterations of the cytoskeletal organization in tumor cell lines by a cardiotonic drug, vesnarinone, through protein tyrosine phosphorylation. Yoshinaka, Y., Katoh, I., Kyushiki, H., Sakamoto, Y. Exp. Cell Res. (1995) [Pubmed]
  17. Vesnarinone causes oxidative damage by inhibiting catalase function through ceramide action in myeloid cell apoptosis. Kondo, T., Suzuki, Y., Kitano, T., Iwai, K., Watanabe, M., Umehara, H., Daido, N., Domae, N., Tashima, M., Uchiyama, T., Okazaki, T. Mol. Pharmacol. (2002) [Pubmed]
  18. Effect of CYP3A inhibition on vesnarinone metabolism in humans. Wandel, C., Lang, C.C., Cowart, D.C., Girard, A.F., Bramer, S., Flockhart, D.A., Wood, A.J. Clin. Pharmacol. Ther. (1998) [Pubmed]
  19. Open channel block of HERG K(+) channels by vesnarinone. Kamiya, K., Mitcheson, J.S., Yasui, K., Kodama, I., Sanguinetti, M.C. Mol. Pharmacol. (2001) [Pubmed]
  20. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Sănchez-Chapula, J.A., Ferrer, T., Navarro-Polanco, R.A., Sanguinetti, M.C. Mol. Pharmacol. (2003) [Pubmed]
  21. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8. Harada, K., Supriatno, n.u.l.l., Yoshida, H., Sato, M. Int. J. Oncol. (2005) [Pubmed]
  22. Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Yoneda, K., Yamamoto, T., Ueta, E., Osaki, T. Cancer Lett. (1998) [Pubmed]
  23. Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (vesnarinone) on the growth of gastric cancer cell lines. Yokozaki, H., Ito, R., Ono, S., Hayashi, K., Tahara, E. Cancer Lett. (1999) [Pubmed]
  24. Effects of vesnarinone, a novel orally active inotropic agent with an immunosuppressive action, on experimental cardiac transplantation in rats. Yokoyama, H., Momeni, R., Goldstein, C., Mohiuddin, M., Shen, Z., Fyfe, B.S., Whitman, G.J., DiSesa, V.J. Transplantation (1996) [Pubmed]
  25. Prolongation of murine cardiac allograft survival with vesnarinone. Hirozane, T., Matsumori, A., Furukawa, Y., Matsui, S., Matoba, Y., Sasayama, S. J. Mol. Cell. Cardiol. (1997) [Pubmed]
  26. The best of times, the worst of times: the wealth and poverty of heart failure pharmacotherapies: is there a role for vesnarinone? Young, J.B. Drug safety : an international journal of medical toxicology and drug experience. (2004) [Pubmed]
  27. Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis. Fujiwara, H., Arima, N., Otsubo, H., Matsushita, K., Hidaka, S., Arimura, K., Kukita, T., Yamaguchi, K., Tanaka, H. Exp. Hematol. (1997) [Pubmed]
  28. Effects of OPC-8212, a new positive inotropic agent, on canine ventricular arrhythmias. Hashimoto, K., Mitsuhashi, H. Br. J. Pharmacol. (1986) [Pubmed]
WikiGenes - Universities